Latest Breaking News On - French cooperative thoracic intergroup - Page 1 : vimarsana.com

Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung.

United statesLevi garrawayRebekka schnellKarsten kleineSimon goldsboroughSileia urechNathalie altermattBruno eschliKirti pandeyKen culverLoren kalmSabine borngrBirgit masjostFrench cooperative thoracic intergroupClinical affairsAmerican cancer society